|Articles|March 8, 2017
Tufts CSDD Releases Results of New Impact Report
A recently completed study reported that the 505(b)(2) approval pathway for new drug applications in the US has not led to shorter approval times.
Advertisement
A recently completed study conducted by Tufts CSDD reported that the 505(b)(2) approval pathway for new drug applications in the US, aimed at avoiding the duplication of studies performed on a previously approved drugs, has not led to shorter approval times.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
How the NIMBLE Study Supported Adherence With Quarterly Dosing of CemdisiranSeptember 18th 2025
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
IQVIA and Veeva Join Forces to Improve Efficiency and Patient OutcomesSeptember 17th 2025
Managing Background Therapies in the NIMBLE Phase III TrialSeptember 17th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
2
Why Clinical Trials Are at a Crossroads and How Site Networks Are the Key to Success
3
Everything to Know About FDA’s Push Towards Radical Transparency in 2025
4
Enhancing Clinical Trial Data Accuracy Through the IQVIA and Veeva Partnership
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
